MXPA05012391A - Tratamiento de trastornos psicoticos y depresivos. - Google Patents
Tratamiento de trastornos psicoticos y depresivos.Info
- Publication number
- MXPA05012391A MXPA05012391A MXPA05012391A MXPA05012391A MXPA05012391A MX PA05012391 A MXPA05012391 A MX PA05012391A MX PA05012391 A MXPA05012391 A MX PA05012391A MX PA05012391 A MXPA05012391 A MX PA05012391A MX PA05012391 A MXPA05012391 A MX PA05012391A
- Authority
- MX
- Mexico
- Prior art keywords
- depression
- compound
- treatment
- psychotic
- psychosis
- Prior art date
Links
- 208000028017 Psychotic disease Diseases 0.000 title abstract 4
- 208000020401 Depressive disease Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- 208000024714 major depressive disease Diseases 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000024254 Delusional disease Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 208000037357 HIV infectious disease Diseases 0.000 abstract 1
- 206010061285 Mental disorder due to a general medical condition Diseases 0.000 abstract 1
- 208000011963 Substance-induced psychotic disease Diseases 0.000 abstract 1
- 231100000393 Substance-induced psychotic disorder Toxicity 0.000 abstract 1
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 201000002545 drug psychosis Diseases 0.000 abstract 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract 1
- 201000003995 melancholia Diseases 0.000 abstract 1
- 208000002851 paranoid schizophrenia Diseases 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
La presente invencion se refiere a un metodo para tratar en mamiferos, incluyendo los seres humanos, estados clinicos y trastornos psiquiatricos seleccionados de trastornos delusorios, psicosis asociadas con la demencia, tales como las psicosis asociadas con la enfermedad de Alzheimer, psicosis asociadas con un sindrome organico del cerebro (por ejemplo, apoplejia, o una infeccion virica tal como una infeccion por HIV) y psicosis inducidas por farmacos, que comprende administrar una cantidad efectiva de un compuesto de formula I (ver formula I): o de una de sus sales de adicion de acidos farmaceuticamente aceptables, la que Ar, n, X e Y son como se definen; la presente invencion tambien se refiere a un metodo para tratar en mamiferos un trastorno depresivo seleccionado de depresion melancolica, depresion grave, depresion psicotica y depresion resistente a los tratamientos, que comprende administrar un compuesto de formula I, o una sal de adicion de acidos farmaceuticamente aceptables de tal compuesto.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47138003P | 2003-05-16 | 2003-05-16 | |
| PCT/IB2004/001546 WO2004100954A1 (en) | 2003-05-16 | 2004-05-03 | Treatment of psychotic and depressive disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA05012391A true MXPA05012391A (es) | 2006-02-02 |
Family
ID=33452443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA05012391A MXPA05012391A (es) | 2003-05-16 | 2004-05-03 | Tratamiento de trastornos psicoticos y depresivos. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20050004137A1 (es) |
| EP (1) | EP1633360A1 (es) |
| JP (1) | JP2007502856A (es) |
| BR (1) | BRPI0410378A (es) |
| CA (1) | CA2525866A1 (es) |
| CL (1) | CL2004000964A1 (es) |
| MX (1) | MXPA05012391A (es) |
| TW (1) | TW200425894A (es) |
| WO (1) | WO2004100954A1 (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003007956A1 (en) | 2001-07-20 | 2003-01-30 | Psychogenics, Inc. | Treatment for attention-deficit hyperactivity disorder |
| MY144968A (en) * | 2005-04-11 | 2011-11-30 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds and their uses as therapeutic agents |
| AR053710A1 (es) | 2005-04-11 | 2007-05-16 | Xenon Pharmaceuticals Inc | Compuestos espiroheterociclicos y sus usos como agentes terapeuticos |
| AR056317A1 (es) * | 2005-04-20 | 2007-10-03 | Xenon Pharmaceuticals Inc | Compuestos de oxindol y composicion farmaceutica |
| WO2007085954A2 (en) * | 2006-01-27 | 2007-08-02 | Pfizer Products Inc. | Aminophthalazine derivative compounds |
| ATE545416T1 (de) * | 2006-10-12 | 2012-03-15 | Xenon Pharmaceuticals Inc | Verwendung von spiro-oxindol-verbindungen als therapeutika |
| CA2666136A1 (en) * | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents |
| AU2007307638A1 (en) * | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Spiro (furo [3, 2-C] pyridine-3-3 ' -indol) -2' (1'H)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain |
| JP5270943B2 (ja) * | 2008-03-28 | 2013-08-21 | 大阪瓦斯株式会社 | フルオレン誘導体およびこのフルオレン誘導体を用いたアミノ基含有フルオレン誘導体の製造方法 |
| BRPI0918949A2 (pt) | 2008-09-22 | 2019-09-24 | Hoffmann La Roche | moduladores de receptores de 5-ht2a e piperazina d3 |
| CA2741029A1 (en) | 2008-10-17 | 2010-04-22 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
| CA2741024A1 (en) * | 2008-10-17 | 2010-04-22 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
| AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
| US20110086899A1 (en) * | 2009-10-14 | 2011-04-14 | Xenon Pharmaceuticals Inc. | Pharmaceutical compositions for oral administration |
| NZ712378A (en) | 2009-10-14 | 2017-05-26 | Xenon Pharmaceuticals Inc | Synthetic methods for spiro-oxindole compounds |
| EP2538919B1 (en) | 2010-02-26 | 2017-07-12 | Xenon Pharmaceuticals Inc. | Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents |
| US8877778B2 (en) | 2010-12-15 | 2014-11-04 | Hoffmann-La Roche Inc. | Benzofurane compounds |
| US8921397B2 (en) | 2011-05-04 | 2014-12-30 | Hoffmann-La Roche Inc. | Benzofurane-piperidine compounds |
| WO2014078568A1 (en) | 2012-11-14 | 2014-05-22 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| MA41169A (fr) * | 2014-12-17 | 2017-10-24 | Acraf | Composés antibactériens à large spectre d'activité |
| TW201636017A (zh) | 2015-02-05 | 2016-10-16 | 梯瓦製藥國際有限責任公司 | 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX173362B (es) * | 1987-03-02 | 1994-02-23 | Pfizer | Compuestos de piperazinil heterociclicos y procedimiento para su preparacion |
| US4831031A (en) * | 1988-01-22 | 1989-05-16 | Pfizer Inc. | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity |
| US4883795A (en) * | 1988-01-22 | 1989-11-28 | Pfizer Inc. | Piperazinyl-heterocyclic compounds |
| DE3923045A1 (de) * | 1989-07-13 | 1991-01-17 | Merck Patent Gmbh | Indolderivate |
| JP3274579B2 (ja) * | 1995-01-12 | 2002-04-15 | 住友製薬株式会社 | 脳血管障害に伴う精神症候治療剤 |
| AU730856C (en) * | 1996-05-07 | 2001-11-15 | Pfizer Inc. | Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol- 3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1H)- indol-2-one(=ziprasidone),it's preparation and it's use as dopamine D2 antagonist |
| ZA977967B (en) * | 1996-09-23 | 1999-03-04 | Lilly Co Eli | Combination therapy for treatment of psychoses |
| IL125951A (en) * | 1997-09-05 | 2003-09-17 | Pfizer Prod Inc | A pharmaceutical composition comprising a piperazinyl-heterocyclic compound for treating tourette's syndrome, obsessive compulsive disorder, chronic motor or vocal tic disorder in a mammal |
| IL127497A (en) * | 1997-12-18 | 2002-07-25 | Pfizer Prod Inc | Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders |
| EP1844769A3 (en) * | 1998-04-14 | 2010-02-10 | The General Hospital Corporation | Methods for treating neuropsychiatric disorders |
| US6387904B2 (en) * | 1998-05-18 | 2002-05-14 | Pfizer Inc | Method of treating glaucoma and ischemic retinopathy |
| JP2002541098A (ja) * | 1999-04-06 | 2002-12-03 | セプラコア インコーポレーテッド | ジプラシドン代謝産物を用いる神経弛緩薬性障害および関連障害を治療するための方法および組成物 |
| CA2324813A1 (en) * | 1999-11-10 | 2001-05-10 | Susan Beth Sobolov-Jaynes | Combination treatment for depression and anxiety |
| US6572890B2 (en) * | 2000-01-13 | 2003-06-03 | Osmotica Corp. | Osmotic device containing venlafaxine and an anti-psychotic agent |
| AU783516B2 (en) * | 2001-04-30 | 2005-11-03 | Warner-Lambert Company | Methods, kits and compositions for using pyrrole derivatives |
| AP1512A (en) * | 2001-06-19 | 2005-12-15 | Mueller Norbert | Use of cox-2 inhibitors for the treatment of schizophrenia, delusional disorders, affective disorders, autism or tic disorders. |
-
2004
- 2004-05-03 WO PCT/IB2004/001546 patent/WO2004100954A1/en active Application Filing
- 2004-05-03 EP EP04730896A patent/EP1633360A1/en not_active Withdrawn
- 2004-05-03 MX MXPA05012391A patent/MXPA05012391A/es unknown
- 2004-05-03 JP JP2006530648A patent/JP2007502856A/ja active Pending
- 2004-05-03 BR BRPI0410378-5A patent/BRPI0410378A/pt not_active IP Right Cessation
- 2004-05-03 CA CA002525866A patent/CA2525866A1/en not_active Abandoned
- 2004-05-05 CL CL200400964A patent/CL2004000964A1/es unknown
- 2004-05-12 US US10/844,079 patent/US20050004137A1/en not_active Abandoned
- 2004-05-12 TW TW093113352A patent/TW200425894A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20050004137A1 (en) | 2005-01-06 |
| CA2525866A1 (en) | 2004-11-25 |
| WO2004100954A1 (en) | 2004-11-25 |
| CL2004000964A1 (es) | 2005-03-18 |
| TW200425894A (en) | 2004-12-01 |
| EP1633360A1 (en) | 2006-03-15 |
| BRPI0410378A (pt) | 2006-06-13 |
| JP2007502856A (ja) | 2007-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA05012391A (es) | Tratamiento de trastornos psicoticos y depresivos. | |
| NL300933I2 (nl) | Letermovir | |
| TW200420550A (en) | Thiazole compounds for the treatment of neurodegenerative disorders | |
| CA2501799A1 (en) | Pyrazole compounds for treatment of neurodegenerative disorders | |
| UA83899C2 (uk) | Сполуки імідазолу для лікування нейродегенеративних розладів | |
| NO20052546L (no) | Substituert arylthiourea og relaterte forbindelser; inhibitorer av viral reproduksjon. | |
| WO2005063734A3 (de) | Substituierte thiophene | |
| HK1100426A1 (en) | Thiadiazolidinones as gsk-3 inhibitors | |
| WO2004013120A8 (en) | Novel benzodioxoles | |
| EA200501098A1 (ru) | Антибактериальные агенты | |
| UA92355C2 (en) | urn:schemas-microsoft-com:office:smarttags2,4-DIAMINO-PYRIMIDINES USED AS AURORAINHIBITORS | |
| MXPA04005156A (es) | Antagonistas del receptor de adenosina a2a. | |
| MXPA04006184A (es) | Compuestos derivados de 1h-pirazolilo, para el uso en enfermedades asociadas con el receptor 5-ht2c. | |
| MXPA05010440A (es) | Amidas del acido isoquinolina-5-sulfonico como inhibidores de la akt (proteina quinasa b). | |
| MX2009005351A (es) | Compuestos utiles para tratar trastornos neurodegenerativos. | |
| EA200601607A1 (ru) | Сульфонамидные соединения для лечения нейродегенеративных расстройств | |
| TW200716152A (en) | Substituted 1,2-ethylendiamines, medicaments comprising said compound, their use and their method of manufacture | |
| CA2534532A1 (en) | Compounds for the treatment of neurodegenerative disorders | |
| MX2020008816A (es) | Derivados de triazina para el tratamiento de enfermedades relacionadas con neurotrofinas. | |
| ATE437855T1 (de) | (4,5,6,7-tetrahydro-1h-indol-7- yl)essigsäurederivate zur behandlung von alzheimer-krankheit | |
| MY138547A (en) | N-substituted nonaryl-heterocyclic nmda/nr2b antagonists | |
| HK1080079A1 (en) | A process for the preparation of 2-methylpiperazine derivative | |
| EP1958939A3 (en) | Pyrazole-amine compounds for the treatment of neurodegenerative disorders | |
| WO2007034326A3 (en) | Imidazole compounds for the treatment of neurological disorders | |
| WO2004022540A3 (en) | Pyridazinone and pyridone derivatives as adenosine antagonists |